OriGene to add antibody expertise with $16M SDIX deal

04/9/2013 | GenomeWeb Daily News (free registration)

SDIX will sell its life science assets to OriGene Technologies for $16 million. The deal is expected to be finalized this quarter. SDIX's knowledge in antibody development and production "will complement OriGene's existing high-throughput monoclonal antibody capacity to develop the highest quality antibodies," OriGene Chairman and CEO Wei-Wu He said.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Director of Operations - GBS
Mayo Clinic
Rochester, MN
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Senior Vice President, Clinical Affairs & Strategic Partnerships
America's Health Insurance Plans (AHIP)
Washington, DC